These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 32349374)

  • 21. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
    Hack SP; Verret W; Mulla S; Liu B; Wang Y; Macarulla T; Ren Z; El-Khoueiry AB; Zhu AX
    Ther Adv Med Oncol; 2021; 13():17588359211036544. PubMed ID: 34377158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
    Weinmann A; Galle PR
    Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on atezolizumab for hepatocellular carcinoma.
    Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
    Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
    Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
    BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
    Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
    Hack SP; Spahn J; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Chow P; Qin S
    Future Oncol; 2020 May; 16(15):975-989. PubMed ID: 32352320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy for renal cell carcinoma - current status].
    Grimm MO; Foller S
    Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.
    Aoki T; Kudo M; Ueshima K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Minami Y; Tsurusaki M; Nishida N
    Liver Cancer; 2024 Feb; 13(1):56-69. PubMed ID: 38344443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular Carcinoma Immunotherapy.
    Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
    Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials.
    Fulgenzi CAM; D'Alessio A; Airoldi C; Scotti L; Demirtas CO; Gennari A; Cortellini A; Pinato DJ
    Eur J Cancer; 2022 Oct; 174():57-67. PubMed ID: 35970037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
    Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ;
    Lancet; 2019 Jun; 393(10189):2404-2415. PubMed ID: 31079938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
    Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
    Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
    Federico P; Petrillo A; Giordano P; Bosso D; Fabbrocini A; Ottaviano M; Rosanova M; Silvestri A; Tufo A; Cozzolino A; Daniele B
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.